Reversal of Ventricular Remodeling With Toprol-XL

NCT00038077 Phase 3 COMPLETED

The purpose of this study is to determine whether treatment with Toprol-XL for 12 months in asymptomatic heart failure subjects will improve their heart structure and thus prevent the progression to symptomatic disease.

Details

Lead sponsor	AstraZeneca
Phase	Phase 3
Status	COMPLETED
Enrolment	300
Start date	2001-08
Completion	2003-09

Conditions

• Heart Failure, Congestive

Interventions

• Seloken ZOK/Toprol-XL
• Seloken ZOK/Toprol-XL
• Placebo

Countries

United States